Shares of Pharmaceutical company Nuvalent climbed 10.9% this evening. Here are some quick facts to get you started if you are interested in the stock:
-
Nuvalent has logged a 73.1% 52 week change, compared to 24.7% for the S&P 500
-
NUVL has an average analyst rating of buy and is -19.4% away from its mean target price of $101.25 per share
-
Its trailing earnings per share (EPS) is $-2.42, which brings its trailing Price to Earnings (P/E) ratio to -33.7. The Health Care sector's average P/E ratio is 27.53
-
The company's forward earnings per share (EPS) is $-3.66 and its forward P/E ratio is -22.3
-
The company has a Price to Book (P/B) ratio of 7.8 in contrast to the Health Care sector's average P/B ratio is 3.61
-
The current ratio is currently 22.8, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
The company's free cash flow for the last fiscal year was $-99739000 and the average free cash flow growth rate is -64.3%